Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance Use and Mental Health Disorders (R01 Clinical Trial Required)
ID: 353531Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353531

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-035.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for research projects aimed at using neuromodulation to explore the continuum of pathophysiology between substance use disorders (SUD) and mental health disorders (MHD). The initiative seeks applications that investigate the effects of neuromodulation on brain circuits and behaviors relevant to both SUD and MHD, requiring studies to include diverse participant criteria and measures of engagement with circuit-level targets. With an estimated funding commitment of $2 million for fiscal year 2025, the NIH plans to award up to four grants, with a maximum project duration of five years. Interested applicants must adhere to strict submission guidelines, with a critical deadline for applications set for July 15, 2024, and can direct inquiries to grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-035-Full-Announcement.html
    RFA-DA-25-035.html
    The NIH, through the Department of Health and Human Services, announces a funding opportunity for research projects focusing on using neuromodulation to explore the connection between substance use disorders (SUD) and mental health disorders (MHD). This initiative aims to assess the impact of neuromodulation techniques on relevant brain circuits, capturing the continuum of pathophysiology between SUD and MHD. Applications must showcase participant involvement with both SUD and MHD, employing diverse approaches to enhance research inclusivity, outlined in the Plan for Enhancing Diverse Perspectives (PEDP), which is mandatory for submission. With an estimated funding commitment of $2 million for fiscal year 2025, the NIH anticipates awarding up to four grants, with flexibility in budget reflecting project requirements and a maximum duration of five years. Applications must adhere to strict submission guidelines, with critical deadlines set for July 15, 2024. The review process emphasizes scientific merit, innovation, and the significance of addressing both SUD and MHD concurrently, underscoring the initiative's commitment to enhancing understanding and treatment approaches for individuals facing these co-occurring issues.
    Similar Opportunities
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype" (RFA-DA-25-057). This initiative aims to develop clinical trials that integrate non-invasive neuromodulation techniques, such as transcranial magnetic stimulation, with established behavioral therapies to address the high relapse rates and cognitive challenges faced by individuals with StUD. The funding opportunity is particularly significant as it seeks to fill the treatment gap for vulnerable populations exhibiting low executive function and impulsive traits, with a total funding amount of $2,000,000 anticipated to support three to five awards over a project period of up to five years. Interested applicants must submit their proposals by November 27, 2024, and can find additional details and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of innovative devices to treat Substance Use Disorders (SUDs). The initiative seeks proposals that focus on advancing neuromodulatory or neurophysiological devices through various stages of the FDA approval process, with an emphasis on understanding treatment mechanisms and their efficacy. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofits, and tribal governments, with a maximum budget of $500,000 per year for the UG3 phase, which lasts up to two years before transitioning to the UH3 phase for an additional three years. Applications will open on November 18, 2023, with awards expected to commence by December 2023; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity aimed at accelerating the development of device-based treatments for Substance Use Disorders (SUDs) under the UG3/UH3 Cooperative Agreement mechanism. This initiative invites applications focused on both pre-clinical and clinical development of neuromodulatory devices, with the goal of advancing these technologies through the FDA approval process. The funding is structured in two phases: the UG3 phase supports milestone achievements for up to $500,000 annually over two years, while the UH3 phase provides continued funding for projects that successfully meet these milestones for an additional three years. Interested applicants can find more information and application guidelines at the provided NIH link, with the submission deadline set for August 13, 2026.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This grant supports projects that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices, focusing on improving spatial and temporal precision and enabling multi-focal approaches for effective treatment delivery. The initiative is crucial for addressing clinical limitations in mental health technologies and encourages collaboration among multidisciplinary teams with expertise in neuroscience, engineering, and regulatory affairs. Interested applicants can apply for up to $275,000 over a two-year project period, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-038.html.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at fostering the development of innovative brain stimulation devices or enhancing existing FDA-approved devices for treating mental health disorders. The initiative seeks applications from multi-disciplinary teams with expertise in neuroscience, engineering, clinical practices, and regulatory matters, focusing on creating devices that offer improved spatial and temporal resolution compared to current technologies. This funding opportunity is critical for advancing treatment methods in mental health care, with no budget limits as long as costs align with project needs, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.